From “Steel Jungle” to “Flexible Smart Manufacturing”: How Single-Use Systems Are Reshaping Vaccine Sterile Processing?

In the field of sterile drug manufacturing, particularly vaccine production, a quiet revolution is underway. In the past, we faced a "steel jungle" of stainless steel tanks, complex piping, and online steam-in-place (SIP) systems; today, lightweight, flexible single-use products are increasingly becoming the mainstream choice. Particularly during the COVID-19 pandemic, single-use technologies played a critical role in the global vaccine supply chain, thanks to their rapid deployment and flexible campaign-switching capabilities

Today, let’s take a deep dive: how do single-use products deliver core value in sterile vaccine processing?

Why is "sterile" so critically demanding in vaccine production?

Vaccines are biological products injected directly into healthy populations—including infants—so their safety profile takes precedence over all else. Unlike chemical drugs, which can be terminally sterilized, most vaccines (e.g., recombinant protein vaccines, viral vector vaccines, mRNA vaccines, etc.) cannot be terminally sterilized because their active ingredients are heat-labile; they must rely entirely on sterile control throughout the entire process.

Traditional stainless-steel equipment relies on CIP (cleaning-in-place) and SIP (sterilization-in-place) to maintain sterility, but this brings challenges such as difficult cleaning validation, high cross-contamination risks, and prolonged equipment downtime. This is where single-use systems come into play.

Core advantages of single-use products:
Addressing the deep-rooted pain points of sterile manufacturing

01 True cross-contamination elimination

Vaccine manufacturers typically develop multiple product pipelines simultaneously, often co-producing influenza, shingles, HPV, and other vaccines in the same facility. Single-use consumables (storage bags, tubing assemblies, connectors) are single-use and disposable, physically and completely breaking the chain of cross-contamination between different batches and different products—an advantage that stainless-steel systems cannot match.

02 Significantly shorter production cycles

By eliminating lengthy CIP/SIP and associated cleaning validation, equipment turnaround efficiency increases by over 50%. For emergency vaccine production in response to outbreaks, a production line pre-fitted with single-use tubing can switch products within hours.

03 Reduced capital investment and dependence on utilities

Without the need for large pure-steam generators, water-for-injection circulation loops, or complex cleaning stations, single-use facilities make pilot plants and vaccine manufacturing sites lighter and more compact—ideal for rapid industrialization in late-stage vaccine development and for regional vaccine filling centers in remote areas.

04 Closed operations, protecting operators and the environment

Vaccine production may involve live viruses (e.g., live-attenuated vaccines, viral vectors). The closed, sterile nature of single-use products, combined with sterile connectors, sterile cutters, sterile tube sealers, and thermoplastic tubing methods, safeguards sterility across all vaccine process steps. It enables closed transfers outside the highest-grade cleanroom areas, protecting both the product from contamination and personnel from exposure to active pathogens.

Figure 1: BioHub^® Sealer

Figure 2: BioHub^® Welder & welding results for different tubing diameters

Figure 3: BioHub^® SC Sterile Cutter

Across the entire vaccine production workflow:
A breakdown of single-use application scenarios

Single-use systems have long since evolved beyond simple storage bags and now penetrate the core unit operations of vaccine manufacturing:

01 Upstream cell culture

Single-use rocking systems and mixing bioreactors (scalable up to 2000 L and beyond) are widely used for high-density culture of Vero cells, CHO cells, insect cells, and others. Pre-irradiated, single-use culture bags integrate pH and DO sensors (or single-use sterile electrode sleeves), aeration tubing, and are ready to use immediately—completely eliminating the nightmare of live virus leakage and incomplete batch-to-batch inactivation.

Figure 4: CytoLinX^® RW Single-Use Rocking System

Figure 5: CytoLinX^® BR Single-Use Bioreactors

02 Virus harvest and purification

Single-use depth filters and single-use hollow-fiber filters are used for cell debris removal; prepacked single-use chromatography columns avoid column performance degradation and validation headaches; entire single-use flow paths can be connected in series to perform purification under closed conditions.

03 Bulk drug substance storage and mixing

Single-use 2D/3D storage bags (from tens of milliliters to thousands of liters), paired with single-use magnetic mixing systems. The ultra-low-temperature tolerance of 2D bags and PC bottles expands the use scenarios for bulk freeze-thaw, enabling low-temperature storage, mixing, and dilution of intermediates.

Figure 6: BioHub^® Storage Bags

04 Formulation and filling

In the final formulation stage, single-use filling tubing, single-use surge bags, and single-use filling needles/systems are widely adopted in BFS (blow-fill-seal) or pre-filled syringe production. Particularly for multivalent vaccine formulations, single-use systems provide residue-free, rapid-switch formulation solutions.

Figure 7: BioHub^® Single-Use Sterile Filling Bag

Technical enablers on the regulatory pathway: E&L and integrity

What pharmaceutical professionals care about most inevitably includes regulatory compliance. Since single-use systems come into direct contact with drug solutions, their extractables and leachables (E&L) studies are of paramount importance for sterility and safety assurance.

• Suppliers are expected to provide comprehensive extractables data in accordance with guidelines such as BPOG, USP <665>, and <1665>, and to conduct leachables toxicological assessments simulating actual process conditions.

• Single-use system integrity verification (e.g., pressure decay method, tracer gas method) is performed both before and after use to ensure that the sterile barrier is foolproof.

In essence, single-use systems adopt a "sterilized-at-manufacture, discarded-after-use" model, shifting part of the heavy validation burden to suppliers with standardized manufacturing capabilities, while drug manufacturers focus on process suitability validation.

BioLink Validation & Analytical Platform

As a CMA- and CNAS-accredited dual-certification laboratory, BioLink's Validation & Analytical Platform has established its validation system in accordance with ICH Q3E, USP <665>, BPOG, and other regulatory and industry guidelines. Our services cover:

✔ Compatibility & E&L Studies

• E/L studies for single-use consumables

• Drug-container compatibility studies

• Extractables studies in compliance with USP <665> and BPOG

✔ Sterilizing Filter Validation

• Chemical compatibility

• Product-wet integrity

• Adsorption studies

• Bacterial survival & challenge testing

• E/L studies

✔ Other Quality & Safety Testing

• Container-closure integrity (CCIT)

• Disinfectant efficacy validation

• Endotoxin & particulate matter testing

• Cleanroom environmental monitoring

Challenges and the future: evolving toward greater intelligence

Of course, single-use products are not perfect. Challenges remain, including supply chain stability, mechanical strength at large-scale culture, and environmental pressure from waste disposal. But the direction is clear: stronger membrane materials and recyclable plastic solutions.

The vaccine plant of the future may no longer be a majestic steel fortress, but rather a flexible assembly of "Lego-like" cleanroom modules, built with countless single-use components to form a safe, efficient, sterile Great Wall.

Single-use technology is transforming vaccine sterile manufacturing from a "heavy tank" into an "agile cavalry." While reducing costs and accelerating technology transfer, it rigorously safeguards the safety baseline of public health. Which single-use systems has your team already introduced into your vaccine processes? What technical challenges concern you most? Feel free to leave a comment and join the discussion.

Follow us for continuous updates on bioprocessing innovations, empowering the development of high-quality biopharmaceuticals.